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In STEMI patients with multi-vessel disease, non-culprit PCI (NIRA) is discouraged by contemporary guidelines. In spite of this, it is not uncommon to 
intervene on culprit infarct related artery (IRA) and NIRA. Accordingly, a systematic review in primary PCI with STEMI comparing IRA vs IRA&NIRA PCI 
was conducted. 
Methods: Medline search of studies describing IRA vs. IRA&NIRA PCI in STEMI (1966-2008) was conducted. Demographics, short and one 
year outcomes were compared combined and separated into prospective and retrospective studies. Results presented as odds ratios with 95% 
confidence intervals. 
Results: 10 studies with 3577 pts. (7 retrospective n=3343 and 3 prospective n=234): 2229 IRA and 1348 IRA&NIRA PCI. In-hospital or 30-day 
events were lower in IRA: mortality 1.31 (0.82-2.12), re-MI 8.81 (3.14-24.7), and MACE 1.15 (0.84-1.57). One-year MACE was lower in IRA PCI 1.24 
(0.97-1.6); although mortality was lower in IRA&NIRA PCI 0.89 (0.62-1.3). Heterogeneity was demonstrated by study designs (figure). In prospective 
design: odds ratio generally favors IRA&NIRA PCI.
Conclusion: Limited information addressing IRA vs. IRA&NIRA PCI in STEMI exists. Evidence supports guideline recommendations although 
heterogeneity by trial design was observed. An appropriately powered randomized trial is required to clarify treatment of multivessel disease during 
primary PCI.
